Читать книгу Current Concepts in Movement Disorder Management - Группа авторов - Страница 59

Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting more than five million people worldwide [1]. Despite significant efforts from the scientific community, pharmacological management has changed little in the past decades, and interventions able to change the progression of the disease (either neuroprotective or disease-modifying) have yet to be introduced. Nevertheless, several treatment options are accepted and widely available for both early and advanced stages of the disease with the ultimate goal being improving patients’ quality of life and functionality. Indeed, treatment of PD, especially in advanced stages, should be carried out by clinicians with expertise in movement disorders as this disorder is a highly heterogeneous disease and treatment needs to be tailored for individual patients depending on several appraisals, including but not limited to patients’ needs, life style, compliance issues, potential side effects (motor and nonmotor), caregiver support, and presence of cognitive decline or other comorbidities. Several recommendations and reviews have been published so far and a summary of medications available in PD is displayed in Table 1 [2–8].